Cockayne Syndrome
Cockayne syndrome (CS) is a very rare autosomal recessive genodermatosis affecting both the skin and the nervous system. It is caused by mutations in genes responsible for transcription-coupled nucleotide excision repair (TC-NER), a pathway that fixes damaged DNA. When cells partly or completely lose the ability to repair DNA damage caused by ultraviolet (UV) light and oxidative stress, they undergo widespread programmed cell death (apoptosis). The result is a characteristic prematurely aged (progeroid) appearance and progressive failure of multiple organs.
In the skin, children with Cockayne syndrome develop severe photosensitivity from the first years of life. Unlike xeroderma pigmentosum (XP), which carries a very high risk of skin cancer, people with CS rarely develop skin malignancies. Instead, they suffer widespread tissue wasting: thinning of the dermis and subcutis, complete loss of facial fat (giving a "bird-like" or aged face), thin, fragile skin, dryness and pigmented spots, along with sclerosis, skin atrophy and progressive hair loss.
At Haute-Derma, managing Cockayne syndrome means recognizing the characteristic skin signs early, measuring photosensitivity with noninvasive methods, and building a layered skin-protection plan. Our priorities are rigorous sun protection, restoring the protective lipid barrier, preventing severe sunburn and improving quality of life, working closely with pediatrics and neurology.
Disease Mechanisms and Clinical Types
Cockayne syndrome stems from a breakdown in the DNA repair machinery that leads to widespread cell damage:
- Faulty TC-NER and the genes involved:
- The ERCC8 gene (CS-A): Accounts for about 20–30% of cases. It encodes the CSA protein, which helps recognize RNA polymerase II when it stalls at a site of DNA damage.
- The ERCC6 gene (CS-B): Accounts for about 70–80% of cases. It encodes the CSB protein, a chromatin remodeler that frees the stalled RNA polymerase so repair enzymes can get in.
- With TC-NER out of action, cells cannot transcribe essential genes after UV damage. Mitochondria deteriorate, reactive oxygen species (ROS) build up, and keratinocytes and nerve cells are driven into apoptosis.
- How skin atrophy and fat loss (lipodystrophy) develop:
- Ongoing apoptosis of fibroblasts and keratinocytes brings production of type I and III collagen to a complete halt.
- Loss of the dermal blood supply and disappearance of fat cells in the subcutis cause the skin's structure to collapse, producing the typical prematurely aged look.
Main Clinical Types: Skin and Whole-Body Features
- CS type I (classic CS): Clear symptoms appear within the first 2 years of life. Babies are born normal but then show poor growth, photosensitivity (redness and blisters after even brief sun exposure), loss of facial fat, deep-set eyes, large ears and progressive neurological decline.
- CS type II (congenital, connatal or severe CS): A very severe form present at birth or even in the womb (intrauterine growth restriction, IUGR). Affected infants have severe skin involvement, congenital cataracts, marked joint contractures and a short life expectancy.
- CS type III (mild, late-onset or atypical CS): Skin and neurological symptoms appear later (in adolescence or adulthood) and progress slowly, and intellectual development is close to normal.
- COFS (cerebro-oculo-facio-skeletal) syndrome: An extremely severe form within the Cockayne/XP spectrum, marked by brain atrophy, cataracts, severe facial malformation and generalized skin atrophy from birth.
How We Diagnose Cockayne Syndrome at Haute-Derma
- Skin examination and assessment of photosensitivity:
- We look for the characteristic facial features: sunken eyes (enophthalmos), a pointed nose, loss of cheek fat, protruding ears and thin, taut facial skin.
- We assess abnormal redness (erythema) and pustules or blisters that appear after brief sun exposure.
- High-frequency skin ultrasound (HFUS, 22–50 MHz) and dermoscopy:
- HFUS: Shows a markedly thinned dermis, loss of the echo band of the subcutaneous fat and fibrotic changes in superficial vessels.
- Dermoscopy: Reveals linear networks of dilated vessels (telangiectasia) and pale spots interspersed with freckle-like hyperpigmentation on sun-exposed skin.
- Post-UV transcription recovery test (RNA synthesis recovery, RRS): Measures how well skin fibroblasts resume RNA synthesis after UV irradiation. In CS, recovery is severely reduced (under 20% of normal).
- Molecular genetic testing: Next-generation sequencing (NGS) identifies homozygous or compound heterozygous mutations in ERCC6 (CS-B) or ERCC8 (CS-A).
Our Treatment and Care Plan at Haute-Derma
Because the underlying genetic cause cannot be cured, our plan at Haute-Derma focuses on preventing UV damage, restoring skin structure and managing local complications:
Rigorous Physical and Chemical Photoprotection
- Broad-spectrum mineral sunscreen: A non-irritating sunscreen with microfine zinc oxide or titanium dioxide, SPF 50+, PA++++, reapplied every 2 hours outdoors.
- Physical barriers: UV-protective clothing (UPF 50+), wide-brimmed hats, UV400 sunglasses to protect the eyes from cataracts, and UVA-blocking film on home and car windows.
Skin Barrier Restoration
- Lipid-replenishing topicals: Products rich in ceramide NP, cholesterol, free fatty acids and ectoin, applied 2–3 times a day to make up for the lipid barrier lost to skin atrophy.
- Topical antioxidants: Natural vitamin E, ferulic acid and low-strength niacinamide help neutralize the ROS that accumulate because TC-NER is defective.
Managing Skin Complications and Drug Warnings
- Sunburn and wound care: For acute redness or blistering, we use cooling hydrogel dressings and a short course of a mild to moderate topical corticosteroid (hydrocortisone or desonide) under medical supervision.
- IMPORTANT WARNING – avoid metronidazole completely: People with Cockayne syndrome must never be given metronidazole (oral or topical). In CS it can cause severe acute liver toxicity (acute severe hepatotoxicity) leading to fatal liver failure.
